---
title: "Reaffirming Buy on NovaBridge Biosciences: Differentiated Givastomig Profile, Expanded Patient Reach, and Strengthened Long-Term Value Proposition"
description: "Analyst Andres Y. Maldonado of H.C. Wainwright has reiterated a Buy rating on NovaBridge Biosciences with a price target of $9.00. He cites the differentiated clinical profile of the lead asset, givas"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275117998.md"
published_at: "2026-02-06T11:26:22.000Z"
---

# Reaffirming Buy on NovaBridge Biosciences: Differentiated Givastomig Profile, Expanded Patient Reach, and Strengthened Long-Term Value Proposition

> Analyst Andres Y. Maldonado of H.C. Wainwright has reiterated a Buy rating on NovaBridge Biosciences with a price target of $9.00. He cites the differentiated clinical profile of the lead asset, givastomig, which shows strong response rates and safety in treating HER2-negative metastatic gastric cancer. The drug's ability to activate T cells in low CLDN18.2 expression environments expands its potential patient base. Maldonado's confidence is bolstered by the planned Phase 2 trial and the company's strategic focus, justifying the Buy rating and price target increase.

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on NovaBridge Biosciences, with a price target of $9.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Andres Y. Maldonado has given his Buy rating due to a combination of factors that underscore NovaBridge Biosciences’ differentiated clinical profile and strategic positioning. He emphasizes that the company’s lead asset, givastomig, has shown robust response rates and durable progression-free survival in first-line HER2‑negative metastatic gastric cancer when combined with Opdivo and chemotherapy, across a broad spectrum of PD‑L1 and CLDN18.2 expression. The early‑stage trial results also indicate a manageable safety profile, with no treatment‑related deaths and mostly low‑grade adverse events, which supports confidence in the drug’s risk‑benefit balance. In Maldonado’s view, these data collectively support the potential for givastomig to become a best‑in‑class CLDN18.2‑targeting bispecific antibody in frontline immune‑chemotherapy regimens.  
Furthermore, Maldonado highlights that givastomig’s ability to activate T cells via 4‑1BB costimulation specifically in CLDN18.2‑positive tumor microenvironments allows it to be effective even at relatively low CLDN18.2 expression levels, significantly enlarging the potential patient pool versus legacy agents like zolbetuximab that require much higher expression thresholds. He also notes emerging evidence of better gastrointestinal tolerability compared with zolbetuximab, which could translate into more practical dosing and broader clinical adoption. The planned global randomized Phase 2 trial against standard of care, combined with management’s clear commitment to prioritizing givastomig and a disciplined capital allocation strategy with an extended cash runway, further reinforce his conviction in the company’s long‑term value creation. These clinical and strategic elements together justify reaffirming the Buy rating and raising the price target, as he sees a favorable risk‑reward profile at current valuation levels.

Y. Maldonado covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, ImmunityBio, and Sutro Biopharma. According to TipRanks, Y. Maldonado has an average return of 26.2% and a 56.52% success rate on recommended stocks.

### Related Stocks

- [NBP.US - NovaBridge Biosciences](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NovaBridge Reports Positive Phase 1b Results For Givastomig In Metastatic Gastric Cancer | NovaBridge Biosciences (NBP) announced positive Phase 1b results for its drug givastomig in combination with nivolumab a | [Link](https://longbridge.com/en/news/271659683.md) |
| Is Chemo‑Free NK Regimen and Global ANKTIVA Push Altering The Investment Case For ImmunityBio (IBRX)? | ImmunityBio has launched the ResQ215B Phase 2 trial for a chemotherapy-free NK-cell regimen, ANKTIVA, in treating indole | [Link](https://longbridge.com/en/news/276002096.md) |
| IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio | Specialty healthcare ETFs can enhance investment portfolios by focusing on distinct sectors like pharmaceuticals, medica | [Link](https://longbridge.com/en/news/276080275.md) |
| X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan | X4 Pharmaceuticals is focusing on advancing mavorixafor for chronic neutropenia, aiming to establish itself in rare bloo | [Link](https://longbridge.com/en/news/276041918.md) |
| Assessing MBX Biosciences (MBX) Valuation After Positive Analyst Sentiment And Pipeline Progress | MBX Biosciences (MBX) has gained attention due to progress in its peptide therapy pipeline and positive analyst sentimen | [Link](https://longbridge.com/en/news/276031364.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.